[摘要] 目的 對比阿托伐他汀與瑞舒伐他汀對冠心病的治療效果。方法 方便選取該院2014年1月—2016年1月診治的冠心病患者200例,分為阿托伐他汀組(A組)以及瑞舒伐他汀組(B組),A組服用阿托伐他汀進行診治,B組服用瑞舒伐他汀進行診治。在診治前、診治后半年以及診治后1年在早上空腹時抽取靜脈血,之后檢測其血脂、三酰甘油等指標。結果 A組血清總膽固醇治療前為(5.94±0.55)mmol/L,6個月后為(4.66±0.44)mmol/L,12個月為(4.00±0.48)mmol/L;B組血清總膽固醇治療前為(6.09±0.49)mmol/L,6個月后為(5.15±0.48)mmol/L,12個月后為(4.76±0.42)mmol/L;B組三酰甘油、同型半胱氨酸指標優于A組,差異有統計學意義,P<0.05。結論 瑞舒伐他汀比阿托伐他汀在治療冠心病的效果上來看結果更加顯著。
[關鍵詞] 阿托伐他汀;瑞舒伐他汀;冠心病
[中圖分類號] R541.4 [文獻標識碼] A [文章編號] 1674-0742(2016)11(c)-0140-03
[Abstract] Objective To compare the therapeutic effect of atorvastatin and atorvastatin on coronary heart disease. Methods Convenient selection from January 2014 to January 2016, 200 patients with coronary heart disease in our hospital were divided into atorvastatin group (group A) and B group (B group), A group were treated with atorvastatin, and the treatment group was treated with atorvastatin. Before the diagnosis and treatment, the second half of the year, as well as 1 years after the diagnosis and treatment of venous blood in the morning fasting, after testing their blood lipids, renal function and other indicators. Results The serum total cholesterol A group before treatment was (5.94±0.55) mmol/L, 6 months after the (4.66 ±0.44) mmol/L, 12 months (4±0.48) mmol/L; serum total cholesterol B group before treatment was (6.09±0.49) mmol/L, 6 months after the (5.15±0.48) mmol/L, 12 months (4.76±0.42) mmol/L; B group of three glycerol, homocysteine and other indicators better than the A group, the difference was statistically significant. Conclusion The effect of atorvastatin in the treatment of coronary heart disease is more significant.
[Key words] Atovatatin; Rosuvastatin; Coronary heart disease
目前針對冠心病患者并沒有特異性的診治方案,在探究過程中能夠了解到,他汀類藥物如:阿托伐他汀與瑞舒伐他汀等藥物能夠有效的緩解心理衰竭的癥狀,改善心功能,但是有關的調脂作用的研究并沒有完善[1-2]。該文方便選取2014年1月—2016年1月在該院進行診治的冠心病病人200例,旨在對比阿托伐他汀與瑞舒伐他汀對冠心病的治療效果并且評價兩個藥物之間的安全性,取得良好的結果,現報道如下。
1 資料與方法
1.1 一般資料
方便選取在該院進行診治的冠心病病人200例,按照其治療方法分為阿托伐他汀組(A組)以及瑞舒伐他汀組(B組),每組病人100例,A組男59例,女41例,平均年齡(70.23±3.23)歲,平均住院時間(1.23±3.45)個月;B組男67例,女33例,平均年齡(71.67±2.79)歲,平均住院時間(1.89±3.15)個月,對所有患者的基本生命體征進行統計學分析,差異無統計學意義(P>0.05),具有可比性?!?br>